Jazz Pharmaceuticals plc

NASDAQ:JAZZ  
139.72
+1.67 (+1.21%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)7.83B
Current PE58.75
Forward PE 11.2
2yr Forward PE 8.34
See more stats
Estimates Current Quarter
Revenue$576.66 Million
Adjusted EPS$4.08
See more estimates
10-Day MA$139.12
50-Day MA$127.05
200-Day MA$122.96
See more pivots

Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ

FIFTH FLOOR, WATERLOO EXCHANGE, WATERLOO ROAD, DUBLIN, IRELAND 4
Ireland
Phone: 353-1-634-7800
Number of Employees: 1360

Description

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinson's disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.